Australia’s First Oral GLP-1 Weight Loss Pill Hits Private Prescriptions as Wegovy and Foundayo Launch

Half a million Australians used GLP-1 injections for weight loss last year, and starting Friday they have a pill option for the first time.

Novo Nordisk’s oral Wegovy (semaglutide) hits private prescription pads this week after a Therapeutic Goods Administration green light in early November, NewsGP reported. The TGA also approved Eli Lilly’s orforglipron (Foundayo) days later, making Australia the latest market — after the US and UK — to offer oral GLP-1 therapy for obesity.

Regulator approves daily new weight-loss pill to replace weekly injections — 9 News Australia

“For many people, the needle has been a real barrier, whether that’s fear of injecting, a preference for tablets, or practical issues like travel and refrigeration,” said Dr Terri-Lynne South, immediate past chair of RACGP Specific Interests Obesity Management. “A daily tablet may help some patients who would otherwise not have started treatment.”

The pill launches at four strengths with a stair-step price: $260 for 1.5 mg, $270 for 4 mg, $280 for 9 mg, and $395 for the 25 mg maintenance dose, per NewsGP. Lilly’s Foundayo is expected between $250 and $370 a month depending on dose, according to the Australian Financial Review as cited by News24. Neither drug is on the Pharmaceutical Benefits Scheme, so every script is full private pay.

“Until obesity medicines are subsidised, access will be determined by what people can afford rather than by clinical need,” Dr South told NewsGP. “Obesity is a chronic disease, and weight regain is common when treatment stops, so it is important to discuss the long-term plan with patients, including cost, before starting.”

The dosing divide

Oral Wegovy is a peptide, so it demands an empty stomach, a sip of water, and a 30-minute fast before food, drink, or other meds — a counseling point Dr South flagged as critical.

Foundayo, a non-peptide small molecule, carries no food or water restrictions and can be taken any time of day, Lilly Australia general manager Dr Manny Simons told 7NEWS. But Foundayo brings its own complexity: significant drug–drug interaction warnings that Wegovy does not share.

Both drugs are indicated for adults with a BMI ≥30, or ≥27 with at least one weight-related comorbidity. Wegovy also carries a cardiovascular risk-reduction indication for adults with established CVD, BMI ≥27, and no type 1 or type 2 diabetes. Foundayo is also approved as an adjunct to diet and exercise for type 2 diabetes.

Australia's First Oral GLP-1 Weight Loss Pill Hits Private Prescriptions as Wegovy and Foundayo Launch
Photo: The Australian

Subsidy stall

The Pharmaceutical Benefits Advisory Committee recommended injectable Wegovy for PBS listing almost a year ago. Federal Health Minister Mark Butler told 7News in August that people with established cardiovascular disease and high BMI would be the initial focus if a pricing deal could be struck, The Australian reported.

“This is too important a class of drugs not to have on the PBS,” he said at the time. No agreement has been announced for either the injectable or the new oral formulations.

“Greater choice will allow doctors to personalise care and help people find an approach they can manage over the long term,” said Dr Mark Mellor, chair of RACGP Specific Interests Obesity Management, speaking to NewsGP. “The best choice is one that suits a person’s health needs and one that they can manage over time.”

Specialist GP Dr Remon Eskandar called the pills “genuinely exciting,” noting patients who hid injectable use from partners because of stigma now have a discreet alternative, The Australian reported. Associate Professor Samantha Hocking, president of the National Association of Clinical Obesity Services, told 7NEWS that 13 million Australian adults live with overweight or obesity, driving urgency for accessible, evidence-based options.

Daily weight loss pill approved for Australian market — 7NEWS Australia

Lilly’s phase 3 program enrolled more than 10,000 patients across 15 countries, including a dozen Australian hospitals and clinics, Simons told News24. Novo Nordisk’s Oceania senior director of medical and regulatory, Dr Ana Svensson, said the pill “opens a door” for eligible patients.

The injectable Wegovy PBS recommendation turns one year old next month.

New weight loss pill Foundayo approved in Australia — 7NEWS Australia